Additionally, enzalutamide monotherapy has outperformed leuprolide monotherapy.36 The prostate cancer community has recently focused much attention on a number of newly created AR proteolysis-targeting chimeras (PROTACs), which were created as SARDs. Here, AR is linked to prostate carcinoma.